CARBIDOPA; ENTACAPONE; LEVODOPA | ORION PHARMA | ||
18.75MG;200MG;75MG | |||
Yes | Yes | ||
2020-Jun-29 | Expired | ||
None | None | ||
None | No | ||
Stalevo, a combination drug consisting of levodopa (aromatic amino acid), carbidopa (aromatic amino acid decarboxylation inhibitor), and entacapone (catechol-O-methyltransferase (COMT) inhibitor) is indicated for the treatment of Parkinson’s disease. Stalevo is to be used: • To substitute (with equivalent strengths of each of the three components) for carbidopa/levodopa and entacapone previously administered as individual products • To replace carbidopa/levodopa therapy (without entacapone) when patients experience the signs and symptoms of end-of-dose “wearingoff” and when they have been taking a total daily dose of levodopa of 600 mg or less and have not been experiencing dyskinesias. |
1 | 0 | 1 |
Total Other Developers | None |
---|
Drugs with Suitability | No |
---|
18.75MG;200MG;75MG | ** | ** | - | - | 1 |
NDA Sales Available | Total Generic Sales Available |
---|---|
No | 1 |
ANDA No | Generic Co | Manufacturer Name | Operations | Manufacturer Address | Country |
---|---|---|---|---|---|
****** | ****** | ***** *************** ******* | *********** | **** ***. *** ** ***, *** ************, **********, ********* ******, ***** (***) | *** |
Download GenUS Drug Report
Research Delta Advisor, G4,Sani Apartment, Bank of india lane, Ellora park, Vadodara 390023
+91 94997 68112
nimish@researchdelta.com